Somatrobol by British Dragon

Human growth hormone works on a fundamentally different timeline than anabolic steroids. Most athletes notice improvements in sleep quality and recovery within the first 2–4 weeks. Measurable fat loss and lean tissue changes become apparent at 6–10 weeks. The most significant physique transformation — the concurrent fat reduction and lean mass improvement that defines a successful HGH cycle — becomes clearly visible at 3–4 months of consistent use. Athletes who stop at 6–8 weeks consistently underestimate the compound because they have not yet reached the phase where its effects accumulate meaningfully. A minimum 3-month commitment is the practical threshold below which HGH rarely justifies its cost.

Add bacteriostatic water to the lyophilized vial by injecting it slowly down the inner wall of the vial — never directly onto the powder cake. Swirl gently; do not shake, vortex, or invert rapidly, as mechanical agitation damages the peptide structure. The fully dissolved solution should be water-clear with no cloudiness or visible particles. Store reconstituted vials at 2–8°C (standard refrigerator) and use within 30 days. Never freeze the liquid solution — freezing destroys the peptide structure. Lyophilized (dry) unreconstituted vials should also be kept refrigerated; brief room temperature exposure during transit is acceptable, but they should not be stored at room temperature long-term.

No. Human growth hormone operates through GH and IGF-1 receptors and does not interact with the hypothalamic-pituitary-gonadal (HPG) axis that governs testosterone production. Running Somatrobol does not suppress LH, FSH, or testosterone — there is no HPTA suppression, and no post-cycle therapy is required specifically for HGH. If Somatrobol is used alongside anabolic steroids (the most common protocol), standard PCT for those compounds applies as normal. The HGH component does not alter PCT timing, duration, or compound selection.

Human growth hormone (HGH) is the compound injected; IGF-1 is the primary mediator of most of its anabolic effects. After subcutaneous HGH injection, the liver produces and releases IGF-1 into systemic circulation, and IGF-1 is what drives protein synthesis, nitrogen retention, and tissue growth at the cellular level. Some athletes inject synthetic IGF-1 directly (IGF-1 LR3) to bypass this step — producing faster onset but with significantly different risk profiles including hypoglycaemia risk and more pronounced insulin-mimetic effects. Somatrobol's indirect mechanism through endogenous IGF-1 production is considerably safer and self-regulating compared to exogenous IGF-1 injection.

Yes — HGH has no androgenic activity and produces no virilization at any standard performance dose. The benefits of body recomposition, fat loss, skin quality, and connective tissue recovery are fully accessible to female athletes. Female athletes typically use the same dose range as males (2–4 IU/day) with the same monitoring considerations. The most relevant female-specific consideration is the insulin resistance risk at higher doses — women may be somewhat more sensitive to this effect. Starting at 2 IU/day and assessing response before escalating is the appropriate approach. As a non-androgenic, non-estrogenic compound, HGH is one of the most broadly applicable performance compounds for female athletes in the entire catalog.

Growth hormone effects build over months of consistent daily dosing - sleep and recovery improve early, body composition changes come gradually.

Exogenous HGH clears from the body within about a day of the last dose, but its effects develop over sustained use.

The main watchpoints are water retention, glucose drift and carpal-tunnel pressure at higher doses - details are on the product page.